Holen Sie sich die Stockscreener-App
1.251
3.77%
-0.049
Handel nachbörslich:
1.25
-0.0010
-0.08%
Schlusskurs vom Vortag:
$1.30
Offen:
$1.3
24-Stunden-Volumen:
671.94K
Relative Volume:
0.64
Marktkapitalisierung:
$85.53M
Einnahmen:
$525.00K
Nettoeinkommen (Verlust:
$-44.76M
KGV:
-1.8806
EPS:
-0.6652
Netto-Cashflow:
$-37.46M
1W Leistung:
-0.71%
1M Leistung:
-29.72%
6M Leistung:
-57.01%
1J Leistung:
-60.41%
1-Tages-Spanne:
$1.2401
$1.3268
1-Wochen-Bereich:
$1.16
$1.43
52-Wochen-Spanne:
$1.16
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
Firmenname
Cardiff Oncology Inc
Sektor
Branche
Telefon
858-952-7570
Adresse
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.251 | 82.73M | 525.00K | -44.76M | -37.46M | -0.6652 |
VRTX
Vertex Pharmaceuticals Inc
|
468.42 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.03 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.40 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.20 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
169.51 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Eingeleitet | Noble Capital Markets | Outperform |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-06-24 | Eingeleitet | Jefferies | Hold |
| 2024-09-06 | Eingeleitet | Craig Hallum | Buy |
| 2022-01-05 | Eingeleitet | William Blair | Outperform |
| 2021-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-09 | Fortgesetzt | Maxim Group | Buy |
| 2020-10-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
Daily Brief Health Care: Abbvie Inc, Blueprint Medicines, Cardiff Oncology, Fusion Antibodies , Guangdong True Health Medical Technology Development, High Tide , Nasos Pharma, Teladoc Health, Inc. and more - Smartkarma
Cardiff Oncology director Gary Pace buys $36,600 in stock By Investing.com - Investing.com Australia
Cardiff Oncology director Gary Pace buys $36,600 in stock - Investing.com UK
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Cardiff Oncology CEO Mani Mohindru buys $29,890 in company stock - Investing.com
Form 4 Cardiff Oncology Inc For: 22 June By Investing.com - Investing.com Nigeria
Cardiff Oncology (CRDF) CEO makes open-market buy of 24,703 shares - Stock Titan
Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market - Stock Titan
CRDF: Phase II Update; Survival Advantage Extended - Yahoo Finance
Cardiff Oncology (CRDF) Stifel 2025 Healthcare Conference Summary - Quartr
Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology (CRDF) director receives 40,565 stock options grant - Stock Titan
Cardiff Oncology (CRDF) director receives grant of 40,565 stock options at $1.59 - Stock Titan
Cardiff Oncology Shareholders Approve Directors and Equity Plan - TipRanks
Cardiff Oncology (CRDF) shareholders back board, auditor and equity plan - Stock Titan
Cardiff Oncology (CRDF) Holds Steady at $1.50 as Key Levels Define Trading RangeProtective Put - newsline.com
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal CancerSlideshow (NASDAQ:CRDF) 2026-06-07 - Seeking Alpha
Lucid Capital Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
CRDF Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Upda - GuruFocus
CRDF Downgraded by Craig-Hallum -- Price Target Lowered to $2.00 - GuruFocus
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Update - GuruFocus
Cardiff Oncology unveils promising Phase 2 onvansertib data - TipRanks
Onvansertib Phase 2 results move Cardiff Oncology (NASDAQ: CRDF) toward Phase 3 - Stock Titan
Cardiff Oncology Inc Call on Updated Phase 2 CRDF-004 Transcript - GuruFocus
Craig-Hallum Downgrades Cardiff Oncology(CRDF.US) to Hold Rating, Announces Target Price $2 - Moomoo
Cardiff Oncology (CRDF) Reports Promising Phase 2 Results for On - GuruFocus
Cardiff Oncology reports positive phase 2 trial results for onvansertib By Investing.com - Investing.com Australia
Cardiff Oncology reports positive phase 2 trial results for onvansertib - Investing.com
Cardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in RAS-Mutated Metastatic Colorectal Cancer, Plans Registrational Study - Quiver Quantitative
Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting - TradingView
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting - The Manila Times
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Clinical-stage biotech CEO in Jefferies health conference fireside chat - Stock Titan
Cardiff Oncology Shares Fall After HC Wainwright, TD Cowen Downgrades - marketscreener.com
CRDF Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
CRDF Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Cardiff Oncology (CRDF) Files Lawsuit Against Nerviano Medical S - GuruFocus
TD Cowen Downgrades Cardiff Oncology to Hold From Buy - Moomoo
H.C. Wainwright cuts Cardiff Oncology stock rating on license termination By Investing.com - Investing.com Canada
TD Cowen downgrades Cardiff Oncology stock rating on license dispute By Investing.com - Investing.com Canada
Finanzdaten der Cardiff Oncology Inc-Aktie (CRDF)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cardiff Oncology Inc-Aktie (CRDF) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jun 18 '26 |
Buy |
1.22 |
30,000 |
36,600 |
1,356,376 |
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
275,000 |
673,750 |
1,330,676 |
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):